Akinchan Bhardwaj։ OCEANIC-STROKE Trial Signals a New Era in Secondary Stroke Prevention
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn:
”A new antithrombotic strategy may finally reduce recurrent ischemic stroke without increasing bleeding
At the American Stroke Association International Stroke Conference 2026, the OCEANIC-STROKE trial presented an important signal in secondary stroke prevention.
Asundexian, a Factor XIa inhibitor, when added to standard antiplatelet therapy, reduced recurrent ischemic stroke without increasing major bleeding.
Key takeaways from this late-breaking abstract:
- ~26% relative reduction in recurrent ischemic stroke
- Reduction in disabling stroke
- No increase in intracranial or major bleeding
- Consistent benefit across age, sex, and stroke subtype
- Favorable composite cardiovascular outcomes
Why this matters:
For decades, efforts to intensify antithrombotic therapy after non-cardioembolic ischemic stroke have been constrained by bleeding risk. FXIa inhibition targets thrombosis biology more selectively, potentially separating efficacy from hemorrhage: “a long-standing unmet need”in stroke prevention.
Important context:
• Phase III, >12,000 patients, global trial
• Non-cardioembolic ischemic stroke / high-risk TIA
• Results are preliminary (conference abstract, not yet peer-reviewed)
If confirmed, FXI inhibition may represent a meaningful shift in how we think about long-term secondary stroke prevention.
Looking forward to the full manuscript and imaging substudy data.”
Stay updated with Hemostasis Today.
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
-
Jun 25, 2026, 15:23Jonas Kingo: ISTH 2026 in Paris Brings the Global Hemostasis Community Together
-
Jun 25, 2026, 15:21Balancing Therapeutic Progress and Emergency Preparedness in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Jun 25, 2026, 15:06Ifeanyichukwu Ifechidere: What If One of the Biggest Myth Fact About APS is Hidden in its Name?
-
Jun 25, 2026, 15:05Gopal Patidar: Advancing Haemovigilance and Global Collaboration at ISBT 2026
-
Jun 25, 2026, 14:52Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety